Equities analysts predict that Endo International plc (NASDAQ:ENDP) (TSE:ENL) will announce $667.85 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Endo International’s earnings. The highest sales estimate is $704.46 million and the lowest is $651.36 million. Endo International reported sales of $634.86 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.2%. The company is expected to issue its next earnings results after the market closes on Thursday, November 4th.
According to Zacks, analysts expect that Endo International will report full-year sales of $2.79 billion for the current financial year, with estimates ranging from $2.74 billion to $2.87 billion. For the next financial year, analysts expect that the firm will report sales of $2.70 billion, with estimates ranging from $2.55 billion to $2.82 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, August 5th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. Endo International had a net margin of 2.46% and a negative return on equity of 94.51%. The business had revenue of $713.83 million during the quarter, compared to the consensus estimate of $657.27 million. During the same quarter in the prior year, the firm earned $0.65 EPS.
A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in shares of Endo International by 15.5% in the first quarter. Geode Capital Management LLC now owns 4,105,987 shares of the company’s stock valued at $30,425,000 after acquiring an additional 549,953 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in Endo International during the first quarter worth $3,546,000. LSV Asset Management raised its stake in Endo International by 1,928.1% during the second quarter. LSV Asset Management now owns 452,259 shares of the company’s stock worth $2,116,000 after acquiring an additional 429,959 shares in the last quarter. Alpha Paradigm Partners LLC acquired a new position in Endo International during the second quarter worth $1,120,000. Finally, Tudor Investment Corp Et Al raised its stake in Endo International by 179.8% during the second quarter. Tudor Investment Corp Et Al now owns 355,531 shares of the company’s stock worth $1,664,000 after acquiring an additional 228,477 shares in the last quarter. 79.73% of the stock is owned by hedge funds and other institutional investors.
ENDP traded down $0.34 during trading on Tuesday, hitting $4.38. The stock had a trading volume of 7,894,115 shares, compared to its average volume of 6,461,291. Endo International has a twelve month low of $1.94 and a twelve month high of $10.89. The stock has a 50 day simple moving average of $3.14 and a two-hundred day simple moving average of $4.53. The company has a market capitalization of $1.02 billion, a PE ratio of 15.64 and a beta of 1.37.
About Endo International
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.